Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Clinical Rheumatology
Published in: Clinical Rheumatology 6/2007

01-06-2007 | Brief Report

Long-term anti-TNFα therapy for ankylosing spondylitis in two patients with chronic HBV infection

Authors: Grigorios T. Sakellariou, Ioannis Chatzigiannis

Published in: Clinical Rheumatology | Issue 6/2007

Login to get access

Abstract

Anti-TNFα therapy for rheumatic diseases appears to be safe in patients with chronic hepatitis C. However, the administration of anti-TNFα agents without initiation of prophylactic antiviral therapy (lamivudine 100 mg/day) in patients with chronic HBV infection results in exacerbation of liver disease. In this report, we describe our experience of long-term anti-TNFα therapy for ankylosing spondylitis in two inactive HBsAg carriers without preemptive antiviral treatment.
Literature
1.
Calabrese LH, Zein N, Vassilopoulos D (2004) Safety of antitumour necrosis factor (anti-TNF) therapy in patients with chronic viral infections: hepatitis C, hepatitis B, and HIV infection. Ann Rheum Dis 63(Suppl 2):ii18–ii24PubMedCrossRef
2.
Furst DE, Breedveld FC, Kalden JR, Smolen JS, Burmester GR, Bijlsma JW et al (2005) Updated consensus statement on biological agents, specifically tumour necrosis factor α (TNFα) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005. Ann Rheum Dis 64(Suppl 4):iv2–iv14PubMedCrossRef
3.
Guidotti LG, Ishikawa T, Hobbs MV, Matzke B, Schreiber R, Chisari FV (1996) Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes. Immunity 4:25–36PubMedCrossRef
4.
Ostuni P, Botsios C, Punzi L, Sfriso P, Todesco S (2003) Hepatitis B reactivation in a chronic hepatitis B surface antigen carrier with rheumatoid arthritis treated with infliximab and low dose methotrexate. Ann Rheum Dis 62:686–687PubMedCrossRef
5.
Oniankitan O, Duvoux C, Challine D, Mallat A, Chevalier X, Pawlotsky JM et al (2004) Infliximab therapy for rheumatic diseases in patients with chronic hepatitis B or C. J Rheumatol 31:107–109PubMed
6.
Wendling D, Auge B, Bettinger D, Lohse A, Le Huede G, Bresson-Hadni S et al (2005) Reactivation of a latent precore mutant hepatitis B virus related chronic hepatitis during infliximab treatment for severe spondyloarthropathy. Ann Rheum Dis 64:788–789PubMedCrossRef
7.
Roux CH, Brocq O, Breuil V, Albert C, Euller-Ziegler L (2006) Safety of anti-TNFα therapy in rheumatoid arthritis and spondylarthropathies with concurrent B or C chronic hepatitis. Rheumatology (Oxford) (in press)
8.
Esteve M, Saro C, Gonzalez-Huix F, Suarez F, Forne M, Viver JM (2004) Chronic hepatitis B reactivation following infliximab therapy in Crohn’s disease patients: need for primary prophylaxis. Gut 53:1363–1365PubMedCrossRef
9.
Ueno Y, Tanaka S, Shimamoto M, Miyanaka Y, Hiyama T, Ito M et al (2005) Infliximab therapy for Crohn’s disease in a patient with chronic hepatitis. B Dig Dis Sci 50:163–166CrossRef
10.
del Valle Garcia-Sanchez M, Gomez-Camacho F, Poyato-Gonzalez A, Iglesias-Flores EM, de Dios-Vega JF, Sancho-Zapatero R (2004) Infliximab therapy in a patient with Crohn’s disease and chronic hepatitis B virus infection. Inflamm Bowel Dis 10:701–702CrossRef
11.
Millonig G, Kern M, Ludwiczek O, Nachbaur K, Vogel W (2006) Subfulmitant hepatitis B after infliximab in Crohn’s disease: need for HBV-screening? World J Gastroenterol 12:974–976PubMed
Metadata
Title
Long-term anti-TNFα therapy for ankylosing spondylitis in two patients with chronic HBV infection
Authors
Grigorios T. Sakellariou
Ioannis Chatzigiannis
Publication date
01-06-2007
Publisher
Springer-Verlag
Published in
Clinical Rheumatology / Issue 6/2007
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-006-0392-1

Other articles of this Issue 6/2007

Clinical Rheumatology 6/2007 Go to the issue

Case Report

Aneurysm of the internal carotid artery in a female patient of Behcet’s disease: a rare presentation

Case Report

Intravenous immunoglobulin in the treatment of resistant subacute cutaneous lupus erythematosus: a possible alternative

Brief Report

Bone mineral density evolution in young premenopausal women with idiopathic osteoporosis

Original Article

Is three selected parameters adequate to monitor rheumatoid arthritis?

Case Report

Weber–Christian disease presenting with intractable fever and periorbital swelling mimicking angioedema

Brief Report

Deflazacort induced stronger immunosuppression than expected
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits